Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...